Study of Virus-Induced Immunosuppression from HIV-1 and SARS-CoV-2 Impact on Blood Stem Cells and Bone Marrow Function

What this Trial Is About

This research explores how HIV-1 and SARS-CoV-2 viruses may infect long-lived hematopoietic stem and progenitor cells HSPCs that have the ability to renew themselves. These infected cells could become a lasting source of infected cells, affecting the process of blood cell formation known as hematopoiesis. The study aims to understand virus-induced immunosuppression, a condition where immune cells decline due to viral infections, which is serious and seen in chronic HIV-1 and some COVID-19 patients. The mechanisms behind this immunosuppression and effective treatments are not well known. The study will evaluate which types of HSPCs are targeted by HIV-1 and SARS-CoV-2, both inside the body and in laboratory settings. It will also assess whether infected HSPCs change the bone marrow environment by increasing inflammatory signals that could harm the production of lymphocytes, a type of immune cell. This observational study does not involve treatments but focuses on detailed evaluations. Participants include HIV-positive patients with various viral loads and healthy individuals who have had bone marrow biopsies or myelograms as part of their medical care at Ambroise Par Hospital. Researchers will monitor the bone marrow environment over a year to see how infected cells may affect it. Various tests and analyses will be performed to measure immune status and bone marrow changes throughout the study until its completion in March 2026.

Viral Infection of HSPC Impacts Hematopoiesis